



JC02 Rec'd PCT/PTO 06 JUN 2005

PATENT

PCT

2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: AVERY, et al.
Serial No.: 10/523,964
Filed: August 7, 2003
For: Novel Antigiardial Agents and Methods of Use Thereof
Group Art Unit: Not yet assigned
Attorney's Docket No. 11636N/021304
Customer No. 32885

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION BEFORE MAILING DATE OF A FIRST ACTION ON THE MERITS)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 1, 2005

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and §1.98, applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

I. List of Patents, Publications or Other Information

The Patents, publications, or other information submitted for consideration by the Office are listed on Form PTO-1449(s), attached hereto.

II. Copies

The Patents and other publications listed on the attached Form PTO-1449 are in the English language or an English language abstract is provided.

In view of the waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(iii) copies of the cited U.S. Patents and published applications are not attached.

Additionally, non-patent publications listed on Form PTO-1449, but not enclosed, may have been listed on the International Search Report, a copy of which was submitted with filing under 35 U.S.C. § 371.

III. Concise Explanation of Relevance

The attached documents, publications, and/or other information attached hereto are in the English language and do not require a statement of relevancy.

IV. Fees

The IDS is being filed under 37 C.F.R. §1.97(b); within three months of the filing date of a national application or before mailing date of a first action on the merits, whichever event occurs last. No fee or statement is required

V. Payment of Fees

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary).

Respectfully submitted,



Richard S. Myers, Jr.
Registration Number 42,022
STITES & HARBISON PLLC
424 Church Street, Suite 1800
Financial Center
Nashville, TN 37219-2376
(615) 244-5200
Customer No. 32885

Attorney for Applicant

U.S. Department of Commerce
Patent & Trademark Office

Atty. Docket No.
11636N/021304

Serial No.
10/523,964

Customer No. 32885

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicant

AVERY, et al.

Filing Date
August 7, 2003

Group
Not yet assigned

[illegible]

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Name	Class	Subclass	Translation	
							Yes	No
		WO94/23716	October 27, 1994	Gorbach, et al.				
		WO95/03293	February 2, 1995	Nogradi, et al.				
		WO96/39832	December 19, 1996	Kung				
		WO99/48496	September 30, 1999	Kelly, et al.				

MISCELLANEOUS DOCUMENTS

		Belmar, et al.; Synthesis of new mesogenic compounds having the isoflavone core group; Liquid Crystals; 1999; Vol. 26(1); pp. 75-81.
		Brandi, M. L. Phytoestrogens and menopause. Environmental Toxicology and Pharmacology 1999, 7, 213-216.
		Brandi, M. L. Natural and synthetic isoflavones in the prevention and treatment of chronic diseases. Calcified Tissue International 1997, 61, S5-S8.
		Calzada, F.; Meckes, M.; Cedillo-Rivera, R. Antiamoebic and anti giardial activity of plant flavonoids. PLANTA MEDICA 1999, 65, 78-80.
		Calzada, et al; Geranins A and B, New Antiprotozoal A-Type Proanthocyanidins from Geranium niveum. Journal of Natural Products 1999, 62, 705-709.
		Chakravarti, et al.; Chemical Abstracts; Columbus, OH, US; Sci. Cult; Vol. 28; 1962; pp 242-243.

Examiner:

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce
Patent & Trademark Office

Atty. Docket No.
11636N/021304

Serial No.

10/523,964

Customer No. 32885

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicant

AVERY, et al.

Filing Date
August 7, 2003

Group	Not yet assigned
-------	------------------

[illegible]

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Name	Class	Subclass	Translation	
							Yes	No
		WO99/49862	October 7, 1999	Khan, et al.				
		WO00/49009	August 24, 2000	Heaton, et al.				
		WO00/62765	October 26, 2000	Barlaam, et al.				
		WO00/62774	October 26, 2000	Banz, et al.				

MISCELLANEOUS DOCUMENTS

	Chang, et al.; Excretion of radioactive daidzein and dquol as monosulfates and disulfates in the urine of the laying hen; CA J. Biochem; 1975; Vol 53(2); pp. 223-230.
	Chudgar, et al.; Studies in isoflavones. I. Bromination, iodination, and nitration of 7-hydroxyisoflavone. J. Inst. Chem. (India) 1967, 39, 203-208..
	Della Valle, F.; Romeo, A. 2-Haloresorcinols. Eur. Pat. Appl.; (Fidia S.p.A., Italy). Ep, 1985, 31 pp
	ElSohly, et al.; Antigiardial isoflavones from Machaerium aristulatum. Planta Medica (1999), 65(5), 490.
	Farkas, et al.; Chemical Abstract; Columbus, OH; Chem. Ber; Vol. 91; 1958; pp. 2858-2861.
	Gennari, C. Calcitonin, bone-active isoflavones and vitamin D metabolites. Osteoporosis International 1999, 9, 81-90.
	Gillin, et al.; Cell biology of the primitive eukaryote Giardia lamblia. Annual Review of Microbiology 1996, 50, 679-705.
	Goldwyn, et al.; Promotion of health by soy isoflavones: efficacy, benefit and safety concerns. Drug Metabolism and Drug Interactions 2000, 17, 261-289.

Examiner:

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce
Patent & Trademark Office

Atty. Docket No.
11636N/021304

Serial No.

10/523,964

Customer No. 32885

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicant

AVERY, et al.

Filing Date
August 7, 2003

Group	Not yet assigned
-------	------------------

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

MISCELLANEOUS DOCUMENTS

	Harborne, et al.; Chemical Abstracts, Columbus, OH; J. Org. Chem; Vol. 28; 1963; pp 881-882.
	Jain, et al.; Flavonoids from <i>Eschscholzia californica</i> ; Phytochemistry; 1996; Vol 41(2); pp. 661-662.
	Joshi, et al.; Studies in the synthesis of furochromones. Part VIII Synthesis of furoisoflavones; IN J. Chem. Sec B: Org Chem Incl Med Chem.; 1988; Vol 27B(9); pp. 806-810.
	Kalra, et al; Synthesis of 2-hydroxyisoflavones; Indian J. Chem; Vol. 5(7); 1967; pp 287-290.
	Keister, D. B. Axenic culture of <i>Giardia lamblia</i> in TYI-S-33 medium supplemented with bile. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE 1983, 77, 487-488.
	Khan, et al.; Antigiardial Activity of Isoflavones from <i>Dalbergia frutescens</i> Bark. Journal of Natural Products 2000, 63, 1414-1416.
	Khan, et al.; Antigiardial Activity of Isoflavones from <i>Dalbergia frutescens</i> Bark. Journal of Natural Products (2000), 63(10), 1414-1416.

Examiner:

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce
Patent & Trademark Office

Atty. Docket No.
11636N/021304

Serial No.

10/523,964

Customer No. 32885

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicant

AVERY, et al.

Filing Date
August 7, 2003

Group

Not yet assigned

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

MISCELLANEOUS DOCUMENTS

		Khilya, et al.; Reaction of isoflavones and their 4-thioxo analogs with hydroxylamine; <i>Ukrainskii Khimicheskii Zhurnal</i> (Russian Edition); 1990; Vol. 56(3); pp. 280-286.
		Khilya, et al.; Synthetic analogs of natural isoflavones; <i>Ukrainskii Khimicheskii Zhurnal</i> (Russian Edition); 1984; Vol. 50(12); pp. 1301-1306.
		Kiehlmann, E.; Lauener, R. W. Bromophloroglucinols and their methyl ethers. <i>Can. J. Chem.</i> 1989, 67, 335-344.
		Kitagawa, et al.; Aryloxyacetic acid diuretics with uricosuric activity. II. Substituted "(4-oxo-4H-1-benzopyran-7-yl)oxy"acetic acids and the related compounds; <i>Chem & Pharm Bulletin</i> ; 1991; Vol. 39(10); pp. 2681-2690.
		Lal, G. S.; Pez, G. P.; Syvret, R. G. Electrophilic NF Fluorinating Agents. <i>Chemical Reviews</i> (Washington, D. C.) 1996, 96, 1737-1755.
		Lehmann, et al; Studies on biological activity of isoflavones in cultivated V79 cells; <i>Lebensmittelchemie</i> ; 1999; Vol. 53(5); p. 124.

Examiner:

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Comparable to Form PTO-1449		U.S. Department of Commerce Patent & Trademark Office		Atty. Docket No. 11636N/021304		Serial No. 10/523,964	
				Customer No. 32885			
				Applicant AVERY, et al.			
				Filing Date August 7, 2003		Group Not yet assigned	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)							
Examiner Initial		Document No.	Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Name	Class	Subclass	Translation Yes No
MISCELLANEOUS DOCUMENTS							
		Mineno, et al.; Solution-phase parallel synthesis of an isoflavone library for the discovery of novel antiangiogenic agents; Combinatorial Chemistry and High Throughput Screening; Vol. 5(6); 2002; pp. 481-487.					
		Messina, M. Soyfoods and soybean phyto-estrogens (isoflavones) as possible alternatives to hormone replacement therapy (HRT). European Journal of Cancer 2000, 36, S71-S72.					
		Moolasart, P. Giardia lamblia in AIDS patients with diarrhea. JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND 1999, 82, 654-659.					
		Polkowski, K.; Mazurek, A. P. Biological properties of genistein a review of in vitro and in vivo data. Acta Polonica Pharmaceutica 2000, 57, 135-155.					
		Ruenitz, P. C. Drugs for osteoporosis prevention: mechanisms of bone maintenance. Curr. Med. Chem. 1995, 2, 791-802.					
		Sepulveda-Boza, et al.; The preparation of new isoflavones; Synthetic Comm; 2001; Vol. 32(12); pp. 1933-1940.					
		Shao, et al.; Studies on the synthesis and structure-antihypoxia activity relations of daidzein, an active principle of Pueraria pseudohiruta, and its derivatives; Yaoxue Xuebao; 1989; Vol 15(9); pp. 538-547.					
Examiner:		Date Considered					
* Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

U.S. Department of Commerce
Patent & Trademark Office

Atty. Docket No.
11636N/021304

Serial No.
10/523,964

Customer No. 32885

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicant

AVERY, et al.

Filing Date
August 7, 2003

Group	Not yet assigned
-------	------------------

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

MISCELLANEOUS DOCUMENTS

		Shirataki, et al.; Relationship between cytotoxic activity and radical intensity of isoflavones from <i>Sphora</i> species; <i>Anticancer Research</i> ; 2001; Vol. 21(4A); pp. 2643-2648.
		Sun, W.-C.; Gee, K. R.; Klaubert, D. H.; Haugland, R. P. Synthesis of fluorinated fluoresceins. <i>Journal of Organic Chemistry</i> 1997, 62, 6469-6475.
		Suthar, A. C.; Banavalikar, M. M.; Biyani, M. K. Pharmacological activities of genistein, an isoflavone from soy (Glycine max): Part II-Anti-cholesterol activity, effects on osteoporosis & menopausal symptoms. <i>Indian Journal of Experimental Biology</i> 2001, 39, 520-525.
		Traxler, et al.; Use of a Pharmacophore Model for the Design of EGFR Tyrosine Kinase Inhibitors: Isoflavones and 3-Phenyl-4(1H)-quinolones; <i>J. Medicinal Chem</i> ; 1999; Vol. 42(6); pp. 1018-1026.
		Upcroft, P.; Upcroft, J. A. Drug targets and mechanisms of resistance in the anaerobic protozoa. <i>Clinical Microbiology Reviews</i> 2001, 14, 150-164.
		Varga, et al.; Stability and chemical reactivity of 7-isopropoxyisoflavone (ipriflavone); <i>European J. of Organic Chem</i> ; 2001; Vol. 20; pp. 3911-3920.
		Vasil'Ev, et al.; Synthesis and anabolic action of modified isoflavones; <i>Khimiko-Farmatsevticheskii Zhurnal</i> ; 1990; Vol. 24(9); pp. 38-41.

Examiner:

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce
Patent & Trademark Office

Atty. Docket No.
11636N/021304

Serial No.

10/523.964

Customer No. 32885

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicant

AVERY, et al.

Filing Date
August 7, 2003

Group
Not yet assigned

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

MISCELLANEOUS DOCUMENTS

		Vesy, C. J.; Peterson, W. L. Review article: the management of Giardiasis. ALIMENTARY PHARMACOLOGY AND THERAPEUTICS 1999, 13, 843-850.
		Waechaelae, et al; Synthesis and labeling of isoflavone phytoestrogens, including daidzein and genistein; Proceedings of the Society for Experimental Bio and Med; 1995; Vol. 208(1); pp. 27-32.
		Wahala, K.; Hase, T. A. Expedient synthesis of polyhydroxyisoflavones. J. Chem. Soc., Perkin Trans. 1 1991, 3005-3008.
		Wilson, M. E. Public Health & Preventive Medicine; 14th ed.; Appleton & Lange: Stamford, CT, 1998; pp. 252-254.
		Wright, C. W.; Melwani, S. I.; Phillipson, J. D.; Warhurst, D. C. Determination of anti-giardial activity in vitro by means of soluble formazan production. Trans. R. Soc. Trop. Med. Hyg. 1992, 86, 517-519.
		Yamaguchi, M. Isoflavone and bone metabolism: its cellular mechanism and preventive role in bone loss. Journal of Health Science 2002, 48, 209-222.
		Yang, J.-J.; Su, D.; Vij, A.; Hubler, T. L.; Kirchmeier, R. L.; Shreeve, J. n. M. Synthesis of 4-fluororesorcinol and 4-trifluoromethylresorcinol. Heteroatom Chemistry 1998, 9, 229-239.

Examiner:

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce
Patent & Trademark Office

Atty. Docket No.
11636N/021304

Serial No.

10/523,964

Customer No. 32885

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicant

AVERY, et al.

Filing Date
August 7, 2003

Group	Not yet assigned
-------	------------------

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

MISCELLANEOUS DOCUMENTS

[illegible]

Examiner:

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.